These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 16887388)
1. Biotechnology SMEs, start-ups, spin-offs or microenterprises are they molecules coming from the research results? If so, what place do they hold in the global industrial tissue? Doddoli R Biomol Eng; 2007 Feb; 24(1):3-4. PubMed ID: 16887388 [TBL] [Abstract][Full Text] [Related]
2. France to focus on a few biotech clusters. Balcon E Nat Biotechnol; 2004 Sep; 22(9):1063-4. PubMed ID: 15340457 [No Abstract] [Full Text] [Related]
3. Tech transfer revs up. Lawrence S Nat Biotechnol; 2006 Jan; 24(1):13. PubMed ID: 16404380 [No Abstract] [Full Text] [Related]
4. Almost in bloom. Marris E Nat Biotechnol; 2008 Apr; 26(4):471-2. PubMed ID: 18392030 [TBL] [Abstract][Full Text] [Related]
6. Global update: Scotland. Courtney A Regen Med; 2011 Nov; 6(6 Suppl):150-2. PubMed ID: 21999279 [TBL] [Abstract][Full Text] [Related]
7. Biotechnology and new companies arising from academia. Vallance P Lancet; 2001 Nov; 358(9295):1804-6. PubMed ID: 11734259 [TBL] [Abstract][Full Text] [Related]
8. Perspective: Biotech funding trends: Insights from entrepreneurs and investors. Gruber AC Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460 [TBL] [Abstract][Full Text] [Related]
9. The development of China's medical biotech industry needs to be driven by innovation. Yu Z; Dai Y Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752 [TBL] [Abstract][Full Text] [Related]
10. Spin-offs versus start-ups as business models in biotechnology. Persidis A; De Rubertis F Nat Biotechnol; 2000 May; 18(5):570-1. PubMed ID: 10802637 [No Abstract] [Full Text] [Related]
11. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs. Kang KN; Lee YS Biotechnol Lett; 2008 Oct; 30(10):1699-704. PubMed ID: 18506395 [TBL] [Abstract][Full Text] [Related]
12. Enthusiasm cools in Q2. Lawrence S Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352 [No Abstract] [Full Text] [Related]
13. Could bank loans solve Europe's biotech financing slump? Mitchell P Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276 [No Abstract] [Full Text] [Related]
14. SusChem industrial biotechnology--potentials and challenges in industrial biotech in Europe. Burel C ChemSusChem; 2008; 1(8-9):773-4. PubMed ID: 18686284 [No Abstract] [Full Text] [Related]
16. University spin-offs: opportunity or challenge? Peng X Nat Mater; 2006 Dec; 5(12):923-5. PubMed ID: 17139301 [No Abstract] [Full Text] [Related]
17. San Diego. Howard K Nature; 2003 Dec; 426(6967):689. PubMed ID: 14668871 [No Abstract] [Full Text] [Related]
18. Biotech holds its own in Q2. Lawrence S Nat Biotechnol; 2004 Aug; 22(8):938. PubMed ID: 15286634 [No Abstract] [Full Text] [Related]
19. Europe's biotech industry still losing to US, say analysts. Schiermeier Q Nature; 2001 May; 411(6836):404. PubMed ID: 11373636 [No Abstract] [Full Text] [Related]
20. Who took the tech out of biotech? Silverman E Nat Biotechnol; 2006 Mar; 24(3):255-6. PubMed ID: 16525373 [No Abstract] [Full Text] [Related] [Next] [New Search]